
May faces pressure for cross-party talks over NHS future
pharmafile | March 26, 2018 | News story | Medical Communications, Sales and Marketing | NHS, Theresa May, UK government, biotech, drugs, pharma, pharmaceutical
A group of close to 100 MPs have demanded that Theresa May set up a parliamentary commission to plot the long-term future of the NHS.
The question, as it often is with the NHS, revolves around funding, in relation to the pressures that the system is being placed under.
The strongly-worded letter to Theresa May identifies that the “system wide pressures over recent weeks cannot be wholly attributed to ‘flu and the cold snap’. They also reflect more serious underlying issues facing the NHS, public health and social care. These systems are overstretched, poorly integrated and are no longer able to keep pace with rising demand and the cost pressures of new drugs and technologies.”
In response, the demand, backed by 98 MPs, call for a special select committee, comprised of members of both Houses of Parliament.
Its proposed aims would be to determine the scale of demand on the service moving forward to 2034. Beyond this, it would also determine the cost of the service and look at funding options of the service, in order to plan for the service’s long-term future.
The move has been led by Dr Sarah Wollaston, a Conservative MP and former GP, but has been backed by a number of politicians across the political spectrum; the letter was coordinated between the Liberal Democrat’s Norman Lamb, and Labour’s Frank Field.
The government plans to release a green paper on funding for social care in the summer but the letter states that this does not go far enough, instead it states that “There is an urgent need to take a whole system approach, including to prevention, if we are to reduce demand”.
There is now some momentum behind finding an alternative way to fund the NHS, with more open discussions of raising taxes to pay for the service or even a specific ‘NHS tax’ that would be specifically allocated to the health service.
The letter to May makes mention of such a tax and Jeremy Hunt has also tiptoed in this direction with recent comments during interviews. Ultimately, the final decision, if any, on this will not be revealed until the Autumn budget.
Ben Hargreaves
Related Content

Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …

Digital platform cuts pharmaceutical quality-record approval times by up to 90%
A digital platform for exchanging pharmaceutical quality records between supply-chain partners is now commercially available, …

“That gap between innovation and delivery was what stood out to me most”
Pharmafile chats with Camunda’s Natosha McNeal about the vital role of delivery, onboarding AI and …






